Sales of Drug-Spiked Nicotine Could Sink E-Cigarettes' Smoking Cessation Chances
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Since Commissioner Gottlieb's appointment, US FDA has challenged END industry more aggressively to eliminate products and advertising targeting children and has said sales to minors could be a focal point of an FDA action to ban all e-cigarette sales. Finding pharmaceutical ingredients in liquid nicotine could make a general ban on e-cigarette sales more likely in addition to imperiling approval for a smoking cessation indication.
You may also be interested in...
Nicotine Poisoning Seizures Darken Cloud Around E-Cigarettes' NRT Potential
FDA for several years has noted opportunity for e-cigarettes and other electric nicotine delivery systems products to help adult smokers switch to a potentially less harmful form of nicotine delivery. "But we’ve also been clear that, even for adults, e-cigarettes are not risk free," says FDA Commissioner Gottlieb and Principal Deputy Commissioner Abernethy. Most seizures reported by youth and young adult e-cigarette users.
With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives
Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.
Health Market News: DXM Sales Age-Restriction Bill Filed, E-Cigarettes Top NRTs In UK Trial
Resp. Matsui, Johnson again introduce bill for national age-18 requirement for OTC DXM sales; E-Cigarettes top NRTs for smoking cessation efficacy in UK trial.